Unknown

Dataset Information

0

ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.


ABSTRACT:

Background

Dolutegravir (DTG)-based antiretroviral therapy (ART) is highly effective and well-tolerated in adults and is rapidly being adopted globally. We describe the design of the ODYSSEY trial which evaluates the efficacy and safety of DTG-based ART compared with standard-of-care in children and adolescents. The ODYSSEY trial includes nested pharmacokinetic (PK) sub-studies which evaluated pragmatic World Health Organization (WHO) weight-band-based DTG dosing and opened recruitment to children MethodsODYSSEY (Once-daily DTG based ART in Young people vS. Standard thErapY) is an open-label, randomised, non-inferiority, basket trial comparing the efficacy and safety of DTG?+?2 nucleos(t) ides (NRTIs) versus standard-of-care (SOC) in HIV-infected children ResultsBetween September 2016 and June 2018, 707 children weighing ?14?kg were enrolled; including 311 ART-naïve children and 396 children starting second-line. 47% of children were enrolled in Uganda, 21% Zimbabwe, 20% South Africa, 9% Thailand, 4% Europe. 362 (51%) participants were male; median age [range] at enrolment was 12.2?years [2.9-18.0]. 82 (12%) children weighed 14 to ConclusionsBy employing a basket design, to include ART-naïve and -experienced children, and nested PK sub-studies, the ODYSSEY trial efficiently evaluates multiple scientific questions regarding dosing and effectiveness of DTG-based ART in children.

Trial registration

NCT, NCT02259127 , registered 7th October 2014; EUDRACT, 2014-002632-14, registered 18th June 2014 ( https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002632-14/ES ); ISRCTN, ISRCTN91737921 , registered 4th October 2014.

SUBMITTER: Moore CL 

PROVIDER: S-EPMC7809782 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.

Moore Cecilia L CL   Turkova Anna A   Mujuru Hilda H   Kekitiinwa Adeodata A   Lugemwa Abbas A   Kityo Cissy M CM   Barlow-Mosha Linda N LN   Cressey Tim R TR   Violari Avy A   Variava Ebrahim E   Cotton Mark F MF   Archary Moherndran M   Compagnucci Alexandra A   Puthanakit Thanyawee T   Behuhuma Osee O   Saϊdi Yacine Y   Hakim James J   Amuge Pauline P   Atwine Lorna L   Musiime Victor V   Burger David M DM   Shakeshaft Clare C   Giaquinto Carlo C   Rojo Pablo P   Gibb Diana M DM   Ford Deborah D  

BMC infectious diseases 20210104 1


<h4>Background</h4>Dolutegravir (DTG)-based antiretroviral therapy (ART) is highly effective and well-tolerated in adults and is rapidly being adopted globally. We describe the design of the ODYSSEY trial which evaluates the efficacy and safety of DTG-based ART compared with standard-of-care in children and adolescents. The ODYSSEY trial includes nested pharmacokinetic (PK) sub-studies which evaluated pragmatic World Health Organization (WHO) weight-band-based DTG dosing and opened recruitment t  ...[more]

Similar Datasets

| S-EPMC9211426 | biostudies-literature
| S-EPMC7616346 | biostudies-literature
| S-EPMC9143889 | biostudies-literature
| S-EPMC9646993 | biostudies-literature
| S-EPMC8205610 | biostudies-literature
| S-EPMC6518930 | biostudies-literature
| S-EPMC7221036 | biostudies-literature
| S-EPMC4865535 | biostudies-literature
| S-EPMC5075068 | biostudies-literature